Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

JAMA - Journal of the American Medical Association

Volumn 323, Issue 18, 2020, Pages 1824-1836

  Sanders, James M ^a,b   Monogue, Marguerite L ^a,b   Jodlowski, Tomasz Z ^c   Cutrell, James B ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ARBIDOL; BETA INTERFERON; CHLOROQUINE; CORTICOSTEROID; CYTOKINE ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FAVIPIRAVIR; HYDROXYCHLOROQUINE SULFATE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; LOPINAVIR PLUS RITONAVIR; OSELTAMIVIR; REMDESIVIR; RIBAVIRIN; TOCILIZUMAB; ADENOSINE PHOSPHATE; ALANINE; AMIDE; AZITHROMYCIN; HYDROXYCHLOROQUINE; IMMUNOLOGIC FACTOR; INDOLE DERIVATIVE; LOPINAVIR; PYRAZINE DERIVATIVE; RITONAVIR; UMIFENOVIR;

ADJUVANT THERAPY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL (TOPIC); CORONAVIRUS DISEASE 2019; DRUG APPROVAL; DRUG EFFICACY; DRUG REPOSITIONING; DRUG TARGETING; EPIDEMIC; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; MALARIA; NONHUMAN; PANDEMIC; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SYSTEMATIC REVIEW; UNITED STATES; VIROLOGY; BETACORONAVIRUS; CORONAVIRUS INFECTION; DRUG EFFECT; PHYSIOLOGY; TREATMENT WITHDRAWAL; VIRUS PNEUMONIA;

ADENOSINE MONOPHOSPHATE; ADRENAL CORTEX HORMONES; ALANINE; AMIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIVIRAL AGENTS; AZITHROMYCIN; BETACORONAVIRUS; CHLOROQUINE; CORONAVIRUS INFECTIONS; HUMANS; HYDROXYCHLOROQUINE; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; INDOLES; LOPINAVIR; OSELTAMIVIR; PANDEMICS; PNEUMONIA, VIRAL; PYRAZINES; RIBAVIRIN; RITONAVIR; WITHHOLDING TREATMENT;

EID: 85083191572     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2020.6019     Document Type: Review

References (98)

1. Zhu N, Zhang D, Wang W,; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382 (8): 727-733. doi: 10.1056/NEJMoa2001017 31978945
2. Chinese Clinical Trials. http://www/chictr.org/enindex.aspx. Accessed March 31, 2020.
3. Hoffmann M, Kleine-Weber H, Schroeder S, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. Published online March 4, 2020. doi: 10.1016/j.cell.2020.02.052 32142651
4. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020; 92 (4): 418-423. doi: 10.1002/jmv.25681 31967327
5. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015; 1282: 1-23. doi: 10.1007/978-1-4939-2438-7-1 25720466
6. Fung TS, Liu DX. Coronavirus infection, ER stress, apoptosis and innate immunity. Front Microbiol. 2014; 5: 296. doi: 10.3389/fmicb.2014.00296 24987391
7. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003; 3 (11): 722-727. doi: 10.1016/S1473-3099(03)00806-5 14592603
8. Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect. 2017; 5 (1):
9. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. [published online March 20, 2020]. J Antimicrob Chemother. 2020;
10. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. Published online March 11, 2020. doi: 10.1016/j.ijantimicag.2020.105938 32171740
11. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. Published online March 4, 2020. doi: 10.1016/j.ijantimicag.2020.105932 32145363
12. National Health Commission and State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia. Accessed March 18, 2020. http://www.chinalawtranslate.com/wp-content/uploads/2020/03/Who-translation.pdf
13. Chloroquine [database online]. Hudson, OH: Lexicomp Inc; 2016. Accessed March 17, 2020. http://online.lexi.com
14. Aralen (chloroquine phosphate) [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2008. Accessed March 17, 2020. http://www.accessdata.fda.gov/drugsatfda-docs/label/2018/006002s045lbl.pdf
15. Yao X, Ye F, Zhang M, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. Published online March 9, 2020. doi: 10.1093/cid/ciaa237 32150618
16. Gautret P, Lagier JC, Parola P, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. Published online March 20, 2020. doi: 10.1016/j.ijantimicag.2020.105949 32205204
17. Chen J, Liu D, Liu L, A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). Published online March 6, 2020. doi: 10.3785/j.issn.1008-9292.2020.03.03
18. Hydroxychloroquine [database online]. Hudson, OH: Lexicomp Inc; 2016. Accessed March 17, 2020. http://online.lexi.com
19. Plaquenil (Hydroxychloroquine sulfate) [package insert]. St Michael, Barbados: Concordia Pharmaceuticals Inc; 2018. Accessed March 17, 2020. http://www.accessdata.fda.gov/drugsatfda-docs/label/2019/009768Orig1s051lbl.pdf
20. Lim HS, Im JS, Cho JY, Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009; 53 (4): 1468-1475. doi: 10.1128/AAC.00339-08 19188392
21. Chu CM, Cheng VC, Hung IF,; HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59 (3): 252-256. doi: 10.1136/thorax.2003.012658 14985565
22. de Wilde AH, Jochmans D, Posthuma CC, Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014; 58 (8): 4875-4884. doi: 10.1128/AAC.03011-14 24841269
23. Cao B, Wang Y, Wen D, A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. Published online March 18, 2020. doi: 10.1056/NEJMoa2001282 32187464
24. Lopinavir/ritonavir [database online]. Hudson (OH): Lexicomp Inc; 2016. Accessed March 17, 2020. http://online.lexi.com
25. Kaletra (Lopinavir and ritonavir) [package insert]. North Chicago, IL: Abbvie; 2019. Accessed March 17, 2020. http://www.accessdata.fda.gov/drugsatfda-docs/label/2019/021226s048lbl.pdf
26. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Accessed March 17, 2020. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
27. Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A. 2017; 114 (2): 206-214. doi: 10.1073/pnas.1617020114 28003465
28. Khamitov RA, Loginova SIa, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures [in Russian]. Vopr Virusol. 2008; 53 (4): 9-13. 18756809
29. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. Published online March 16, 2020. doi: 10.1093/cid/ciaa272 32176772
30. Siegel D, Hui HC, Doerffler E, Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem. 2017; 60 (5): 1648-1661. doi: 10.1021/acs.jmedchem.6b01594 28124907
31. Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. Published online March 5, 2020. doi: 10.1016/j.tmaid.2020.101615 32145386
32. Sheahan TP, Sims AC, Leist SR, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020; 11 (1): 222. doi: 10.1038/s41467-019-13940-6 31924756
33. Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019; 32 (2): 176-186. doi: 10.1097/QCO.0000000000000532 30724789
34. Avigan (favipiravir) [package insert]. Tokyo, Japan: Taisho Toyama Pharmaceutical Co Ltd; 2017, 4th version. Accessed March 25, 2020.
35. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. chinaXiv. Preprint posted March 5, 2020. doi: 10.12074/202003.00026
36. Actemra (tocilizumab) [package insert]. South San Francisco, CA: Genentech, Inc; 2019. Accessed March 17, 2020. http://www.accessdata.fda.gov/drugsatfda-docs/label/2019/125276s127,125472s040lbl.pdf
37. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006; 3 (9):
38. Morra ME, Van Thanh L, Kamel MG, Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis. Rev Med Virol. 2018; 28 (3):
39. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14 (1): 72-73. doi: 10.5582/bst.2020.01047 32074550
40. ClinicalTrials.gov. Accessed March 18, 2020. http://clinicaltrials.gov/
41. Kalil AC. Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA. Published March 24, 2020. doi: 10.1001/jama.2020.4742 32208486
42. Interview with David Juurlink. Coronavirus (COVID-19) update: chloroquine/hydroxychloroquine and azithromycin. JAMA. March 24, 2020. Accessed April 3, 2020. http://edhub.ama-assn.org/jn-learning/audio-player/18337225
43. Osadchy A, Ratnapalan T, Koren G. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol. 2011; 38 (12): 2504-2508. doi: 10.3899/jrheum.110686 22002012
44. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14 (1): 58-60. doi: 10.5582/ddt.2020.01012 32147628
45. Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. [published online February 27, 2020]. J Med Virol. 2020. doi: 10.1002/jmv.25729 32104907
46. Chan KS, Lai ST, Chu CM, Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003; 9 (6): 399-406. 14660806
47. Wu C, Chen X, Cai Y, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. 32167524
48. Foolad F, Aitken SL, Shigle TL, Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients. Clin Infect Dis. 2019; 68 (10): 1641-1649. doi: 10.1093/cid/ciy760 30202920
49. Arabi YM, Shalhoub S, Mandourah Y, Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study. Clin Infect Dis. Published online June 25, 2019. doi: 10.1093/cid/ciz544 31925415
50. Altinbas S, Holmes JA, Altinbas A. Hepatitis C virus infection in pregnancy: an update. Gastroenterol Nurs. 2020; 43 (1): 12-21. doi: 10.1097/SGA.0000000000000404 31990870
51. Wang D, Hu B, Hu C, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. Published online February 7, 2020. doi: 10.1001/jama.2020.1585 32031570
52. Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019; 14 (4): 397-412. doi: 10.1080/17460441.2019.1581171 30849247
53. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020; 19 (3): 149-150. doi: 10.1038/d41573-020-00016-0 32127666
54. Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol. 2016; 90 (19): 8924-8933. doi: 10.1128/JVI.01429-16 27466418
55. Dyall J, Gross R, Kindrachuk J, Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. Drugs. 2017; 77 (18): 1935-1966. doi: 10.1007/s40265-017-0830-1 29143192
56. Pfefferle S, Schöpf J, Kögl M, The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 2011; 7 (10):
57. de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 2011; 92 (pt 11): 2542-2548. doi: 10.1099/vir.0.034983-0 21752960
58. Wang M, Cao R, Zhang L, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30 (3): 269-271. doi: 10.1038/s41422-020-0282-0 32020029
59. Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016; 9 (3): 227-230. doi: 10.1016/j.jiph.2016.04.001 27095301
60. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. Published online March 4, 2020. doi: 10.1002/ddr.21656 32129518
61. American Heart Association. Patients taking angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blocker (ARB) medications should continue therapy as prescribed [news release]. Published March 17, 2020. Accessed March 18, 2020. http://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician
62. European Society for Cardiology. Position statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. Published March 13, 2020. Accessed March 18, 2020. http://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang
63. World Health Organization. WHO R&D blueprint: ad-hoc expert consultation on clinical trials for Ebola therapeutics. Published October 2018. Accessed March 20, 2020. http://www.who.int/ebola/drc-2018/summaries-of-evidence-experimental-therapeutics.pdf
64. Jacobs M, Rodger A, Bell DJ, Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016; 388 (10043): 498-503. doi: 10.1016/S0140-6736(16)30386-5 27209148
65. Holshue ML, DeBolt C, Lindquist S,; Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020; 382 (10): 929-936. doi: 10.1056/NEJMoa2001191 32004427
66. Kujawski SA, Wong K, Collins JP, First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. medRxiv. Preprint posted March 9, 2020. doi: 10.1101/2020.03.09.20032896
67. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017; 93 (7): 449-463. doi: 10.2183/pjab.93.027 28769016
68. Mentré F, Taburet AM, Guedj J, Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2015; 15 (2): 150-151. doi: 10.1016/S1473-3099(14)71047-3 25435054
69. Sissoko D, Laouenan C, Folkesson E,; JIKI Study Group. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea [published correction appears in PLoS Med. 2016;13(4):e1002009]. PLoS Med. 2016; 13 (3):
70. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. [published online February 22, 2020]. Pharmacol Ther. 2020;
71. Chinello P, Petrosillo N, Pittalis S, Biava G, Ippolito G, Nicastri E; INMI Ebola Team. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLoS Negl Trop Dis. 2017; 11 (12):
72. Kumagai Y, Murakawa Y, Hasunuma T, Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther. 2015; 53 (10): 866-874. doi: 10.5414/CP202388 26308176
73. Chen C, Huang J, Cheng Z, Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. medRxiv. Preprint posted March 27, 2020. doi: 10.1101/2020.03.17.20037432
74. Liu C, Zhou Q, Li Y, Research and development of therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020; 6 (3): 315-331. doi: 10.1021/acscentsci.0c00272 32226821
75. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. bioRxiv. Preprint posted March 22, 2020. doi: 10.1101/2020.03.22.002386
76. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395 (10223): 473-475. doi: 10.1016/S0140-6736(20)30317-2 32043983
77. Arabi YM, Mandourah Y, Al-Hameed F,; Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018; 197 (6): 757-767. doi: 10.1164/rccm.201706-1172OC 29161116
78. Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2019; 23 (1): 99. doi: 10.1186/s13054-019-2395-8 30917856
79. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395 (10229): 1033-1034. doi: 10.1016/S0140-6736(20)30628-0 32192578
80. Zhou F, Yu T, Du R, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3 32171076
81. Sanofi. Sanofi and Regeneron begin global Kevzara (sarilumab) clinical trial program in patients with severe COVID-19 [news release]. Published March 16, 2020. Accessed March 18, 2020. http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19
82. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020; 20 (4): 398-400. doi: 10.1016/S1473-3099(20)30141-9 32113510
83. Soo YO, Cheng Y, Wong R, Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004; 10 (7): 676-678. doi: 10.1111/j.1469-0691.2004.00956.x 15214887
84. Arabi Y, Balkhy H, Hajeer AH, Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015; 4: 709. doi: 10.1186/s40064-015-1490-9 26618098
85. Hung IF, To KK, Lee CK, Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52 (4): 447-456. doi: 10.1093/cid/ciq106 21248066
86. Mair-Jenkins J, Saavedra-Campos M, Baillie JK,; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015; 211 (1): 80-90. doi: 10.1093/infdis/jiu396 25030060
87. Shen C, Wang Z, Zhao F, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020. Published online March 27, 2020. doi: 10.1001/jama.2020.4783 32219428
88. Cao W, Liu X, Bai T, High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. Published online March 21, 2020. doi: 10.1093/ofid/ofaa102
89. US Food and Drug Administration. Investigational COVID-19 Convalescent plasma: emergency INDs. Updated April 3, 2020. Accessed March 26, 2020. http://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds
90. Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. bioRxiv. Preprint posted March 11, 2020. doi: 10.1101/2020.03.11.987958.2020
91. Huang C, Wang Y, Li X, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5 31986264
92. Chen N, Zhou M, Dong X, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395 (10223): 507-513. doi: 10.1016/S0140-6736(20)30211-7 32007143
93. Yang X, Yu Y, Xu J, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. Published online February 24, 2020. doi: 10.1016/S2213-2600(20)30079-5 32105632
94. Young BE, Ong SWX, Kalimuddin S,; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. Published online March 3, 2020. doi: 10.1001/jama.2020.3204 32125362
95. Guan WJ, Ni ZY, Hu Y,; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. Published online February 28, 2020. doi: 10.1056/NEJMoa2002032 32109013
96. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) clinical care. Updated March 30, 2020. Accessed March 18, 2020. http://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
97. World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Updated March 13, 2020. Accessed March 18, 2020. http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
98. Kupferschmidt K, Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments. Science. Published March 22, 2020. Accessed March 23, 2020. http://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments#